Literature DB >> 25920759

Efficacy of a combined inactivated porcine reproductive and respiratory syndrome virus vaccine using North American and European strains in specific pathogen free pigs.

Minjoo Yeom1, Kwang-Soo Lyoo2, Bo-Kyu Kang3, Daesub Song4, Bongkyun Park5.   

Abstract

In Korea, porcine reproductive and respiratory syndrome (PRRS) is caused by European (type 1) and North American (type 2) strains of PRRS virus (PRRSV). In the present study, the efficacy of a multi-strain PRRSV vaccine inactivated with binary ethylenimine (BEI) was evaluated in pigs. The vaccine contained one type 1 strain (GCEU0907) and two type 2 strains (GC4019 and GC6262). Three vaccinated groups (four pigs per group) and three mock vaccinated groups (four pigs per group) were challenged with infectious PRRSV (strains GC4019, GC6262 or GCEU0907), then euthanased at 28 days post-infection. Mean anti-PRRSV neutralising antibody titres were significantly higher in the vaccinated groups than in the mock vaccinated groups. Mean blood virus titres in the mock vaccinated groups were significantly higher than those in the vaccinated groups from 5 to 28 days post-infection. On pathological examination, there were less severe macroscopic and microscopic lesions in vaccinated pigs compared with mock vaccinated pigs.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Combined inactivated vaccine; Porcine reproductive and respiratory syndrome virus

Mesh:

Substances:

Year:  2015        PMID: 25920759     DOI: 10.1016/j.tvjl.2015.02.003

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  2 in total

1.  Ability of ELISAs to detect antibodies against porcine respiratory and reproductive syndrome virus in serum of pigs after inactivated vaccination and subsequent challenge.

Authors:  Tatjana Sattler; Jutta Pikalo; Eveline Wodak; Friedrich Schmoll
Journal:  BMC Vet Res       Date:  2016-11-21       Impact factor: 2.741

2.  Assessments of different inactivating reagents in formulating transmissible gastroenteritis virus vaccine.

Authors:  Fujie Zhao; Lintao Liu; Menglong Xu; Xiangli Shu; Lanlan Zheng; Zhanyong Wei
Journal:  Virol J       Date:  2020-10-23       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.